We came across a bullish thesis on The Cigna Group (CI) on Antonio Linares’ Substack. In this article, we will summarize the ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Blue Cross plans are retreating from GLP-1 weight-loss drug coverage after spending hundreds of millions of dollars on the ...

Evernorth, the health services division of The Cigna Group (NYSE: CI) announced a first-of-its-kind pharmacy benefit offering that make weight loss medications WEGOVY® and ZEPBOUND® more ...

Cigna’s new deal with Eli Lilly and Novo Nordisk ... both significantly cheaper than branded injectables like Wegovy. Hims’s platform, which continues to evolve with personalized care and ...

A huge market for compounded versions of Wegovy and rival therapy Zepbound (tirzepatide) from Eli Lilly sprang up while the two drugs were having supply constraints, with both companies trying to ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo Nordisk, after negotiating a price cut with the company, along with Novo ...

Jefferson Health says it has reached a new agreement with Cigna, ensuring that all Jefferson Health hospitals, physician practices, and providers remain in-network, according to a news release ...

Entering text into the input field will update the search result below Home page Seeking Alpha - Power to Investors Search for Symbols, analysts, keywords ...